Renal Cell Carcinoma

$295.00

,

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Kidney cancer is the 10th most common cancer in Europe with overall mortality rates increasing until the late 1980s and early 1990s and thereafter, stabilized. Until recently, renal cell carcinoma (RCC) was thought to represent a monomorphic disease; however, modern genetic characterization has demonstrated different subtypes with specific cell types and molecular metabolism. Imaging diagnostic methods are basic for staging and for new treatment strategies. Moreover, tumor biopsy has been reintroduced in the diagnostic armamentarium, mainly in patients with small masses but also when disseminated tumors need to be treated with new target therapies.

Although TNM stage, Fuhrman grade and Eastern Oncology Group (ECOG) performance status are the most recognized prognostic factor in RCC, active research continues to determine new prognostic factors to classify different risks for death from RCC. Laparoscopy has gained widespread popularity because of a less morbidity and a faster postoperative convalescence. Partial laparoscopic nephrectomy is a demanding operation that can be made depending on the experience of the surgeon, the size or location of the tumor in the kidney. New robotic approaches are being introduced for nephron sparing surgery.

Conversely, cardiac bypass can be necessary for resection of tumors with thrombus extending into the inferior vena cava above the level of hepatic veins. With the advent of modern ablative energies (cryotherapy or radiofrequency) for renal tumors in selected patients with percutaneous or laparoscopic techniques, it is now possible to achieve long cancer specific survival with decreased morbidity. A need for standardization of follow-up after surgery with lifelong protocols has been recognized in last years. Finally, angiogenesis inhibitors have demonstrated a high probability of disease control in patients with metastatic renal carcinomas. Their indication as adjuvant in local advanced tumors as well as the role of nephrectomy in patients with metastatic disease is being evaluated in current clinical trials. (Imprint: Nova Biomedical)

Table of Contents

Table of Contents

Preface

Epidemiology and Hereditary Kidney Cancer Syndromes
(Paloma Pellejero-Pérez, Jorge Garcia-Rodriguez, Jesus Fernandez-Gomez, Department of Urology. Hospital Universitario Central de Asturias, Oviedo, and other)

Histology Types and Molecular Markers of Renal Carcinoma
(V.Blanco, V.Folgueras, N.Fuentes, B.Vivanco, Department of Pathology. Central de Asturias University Hospital, Oviedo, Spain)

Prognostic Factors and Predictive Tools in Localized and Advanced Renal Cancer
(Oscar Rodriguez Faba, Joan Palou, Alberto Breda, Department of Urology, Fundació Puigvert, Barcelona, Spain)

Advances in Imaging Studies for Diagnosis of Renal Carcinoma
(Alicia Mesa, Rafael Menendez-Llano, Amador Prieto, Encarnacion Nava, Department of Radiology, University Hospital of Asturias, Oviedo, Spain)

Surveillance of Small Renal Masses
(J.A. Portillo, M. Domínguez, A. Azueta, P. Lastra, E. Ramos, J.L. Gutiérrez, Department of Urology. Marqués de Valdecilla University Hospital, Santander. Spain, and others)

Surgical Treatment of Renal Carcinoma: An Update
(H. Rodriguez Nuñez, J.A. Gonzalez Dacal, A. Zarraonandia Andraca, M. Ruibal Moldes, V.I. Garcia Riestra, Urology Service. Department of Urology. University Hospital of Pontevedra, Pontevedra, Spain)

Ablative Therapies for the Treatment of Renal Cell Carcinoma
(Plata Bello A., Concepción Masip T., University Hospital of Canary Islands, La Laguna. Spain)

Follow-Up after Treatment of Localized Renal Tumor (Surgery, Surveillance, Ablative Therapies)
(Javier Perez, Department of Urology. Hospital San Agustin, Aviles, Asturias, Spain)

Radiotherapy for Renal-Cell Carcinoma
(H. González-Suárez, I. Jimenez-Garcia, Radiological Oncologist. Department of Radiological Oncology, University Hospital Central of Asturias. Oviedo, Spain, and other)

New Strategies for Advanced Renal Cell Carcinoma
(Emilio Esteban González, Noemi Villanueva Palicio, Carlos Álvarez Fernández, Luisa Sánchez Lorenzo, Pilar Solis Hernández, Department of Medical Oncology Hospital Universitario Central de Asturias, Oviedo, Spain)

Index


Audience: Urologists, Radiologists, Pathologists and Oncologist. This is a complete actualization in renal cancer for several specialists involved in urological oncology

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!